Can a higher dose of eylea help wet AMD patients go longer between eye injections?
NCT ID NCT07390253
First seen Feb 05, 2026 · Last updated May 21, 2026 · Updated 15 times
Summary
This study looks at whether switching to a higher dose (8mg) of the drug Aflibercept can help people with wet age-related macular degeneration (AMD) who are not responding well to the standard 2mg dose. The goal is to see if the stronger dose allows for fewer eye injections while still keeping vision stable. The study involves 50 adults who have already had at least four injections of the standard dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Vienna Institute for Research in Ocular Surgery
Vienna, 1140, Austria
Conditions
Explore the condition pages connected to this study.